Wrap-Up: Vyvgart Targets Four Populations at AAN 2026
Episode Summary
AAN 2026 highlights transformative ADAPT data, expanding Vyvgart across MG subtypes and CIDP, signaling targeted biologics, pediatric advances, and urgent updates to managed care coverage frameworks.